KRAS and cancer: For example, CancerSEEK, a pan-cancer screening test, demonstrated 72% sensitivity and >99% specificity in patients with symptomatic PDAC, which combines cancer-associated genes and proteins, including KRAS and CA 19-9 [66,67].